ZA964486B - Isoxazoline and isoxazole fibrinogen receptor antagonists. - Google Patents
Isoxazoline and isoxazole fibrinogen receptor antagonists.Info
- Publication number
- ZA964486B ZA964486B ZA9604486A ZA964486A ZA964486B ZA 964486 B ZA964486 B ZA 964486B ZA 9604486 A ZA9604486 A ZA 9604486A ZA 964486 A ZA964486 A ZA 964486A ZA 964486 B ZA964486 B ZA 964486B
- Authority
- ZA
- South Africa
- Prior art keywords
- compounds
- isoxazoline
- fibrinogen receptor
- receptor antagonists
- isoxazole fibrinogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/455,436 US5849736A (en) | 1993-11-24 | 1995-05-31 | Isoxazoline and isoxazole fibrinogen receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA964486B true ZA964486B (en) | 1997-12-01 |
Family
ID=23808800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9604486A ZA964486B (en) | 1995-05-31 | 1996-05-31 | Isoxazoline and isoxazole fibrinogen receptor antagonists. |
Country Status (26)
Country | Link |
---|---|
US (2) | US5849736A (sl) |
EP (1) | EP0832076B1 (sl) |
JP (1) | JPH11504651A (sl) |
KR (1) | KR19990022198A (sl) |
CN (1) | CN1202893A (sl) |
AT (1) | ATE245150T1 (sl) |
AU (1) | AU723577B2 (sl) |
BR (1) | BR9609151A (sl) |
CA (1) | CA2222147A1 (sl) |
CZ (1) | CZ374397A3 (sl) |
DE (1) | DE69629116T2 (sl) |
EA (1) | EA000924B1 (sl) |
EE (1) | EE9700312A (sl) |
ES (1) | ES2198483T3 (sl) |
HU (1) | HUP9900102A3 (sl) |
IL (1) | IL118262A (sl) |
LT (1) | LT4416B (sl) |
LV (1) | LV12046B (sl) |
NZ (1) | NZ309944A (sl) |
PL (1) | PL323835A1 (sl) |
RO (1) | RO117324B1 (sl) |
SI (1) | SI9620071A (sl) |
SK (1) | SK162097A3 (sl) |
TW (1) | TW454007B (sl) |
WO (1) | WO1996038426A1 (sl) |
ZA (1) | ZA964486B (sl) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU713235B2 (en) * | 1995-09-29 | 1999-11-25 | Cor Therapeutics, Inc. | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
US6004955A (en) * | 1996-08-15 | 1999-12-21 | Dupont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists |
US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
AU6645998A (en) * | 1996-12-23 | 1998-07-17 | Du Pont Pharmaceuticals Company | Oxygen or sulfur containing heteroaromatics as factor xa inhibitors |
US6022977A (en) * | 1997-03-26 | 2000-02-08 | Dupont Pharmaceuticals Company | Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids |
US6214834B1 (en) | 1997-03-28 | 2001-04-10 | Dupont Pharmaceuticals Company | Integrin inhibitor prodrugs |
WO1998056408A2 (en) * | 1997-06-10 | 1998-12-17 | Regents Of The University Of Minnesota | Inhibitors of microbial adherence or invasion as therapeutic agents and broad-spectrum enhancers of antibiotic therapy |
HRP980291A2 (en) * | 1997-06-16 | 1999-04-30 | Lin-Hua Zhang | Crystalline roxifiban |
PL337831A1 (en) * | 1997-06-19 | 2000-09-11 | Du Pont Pharm Co | Inhibitors of factor xa containing a specificity giving p1 group |
US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
ZA988735B (en) * | 1997-10-06 | 2000-03-23 | Du Pont Pharm Co | An efficient method for the conversion of nitriles to amidines. |
AU736026B2 (en) * | 1997-12-17 | 2001-07-26 | Merck & Co., Inc. | Integrin receptor antagonists |
US6136833A (en) * | 1998-01-16 | 2000-10-24 | Dupont Pharmaceuticals Company | Pharmaceutical formulations and process for their preparation |
WO1999050255A2 (en) | 1998-03-27 | 1999-10-07 | Du Pont Pharmaceuticals Company | Disubstituted pyrazolines and triazolines as factor xa inhibitors |
WO2000000481A1 (en) | 1998-06-29 | 2000-01-06 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
WO2000008001A1 (en) * | 1998-08-07 | 2000-02-17 | Chiron Corporation | Substituted isoxazole as estrogen receptor modulators |
CA2346396C (en) | 1998-10-09 | 2009-04-28 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
EP1131306A2 (en) | 1998-11-18 | 2001-09-12 | Du Pont Pharmaceuticals Company | Isoxazoline fibrinogen receptor antagonists |
US6319937B1 (en) | 1998-11-18 | 2001-11-20 | Dupont Pharmaceuticals Company | Isoxazoline fibrinogen receptor antagonists |
ES2197092T3 (es) | 1999-04-02 | 2004-01-01 | Bristol-Myers Squibb Pharma Company | Sulfonil arilos como inhibidores del factor xa. |
DE60041584D1 (de) * | 1999-07-28 | 2009-04-02 | Aventis Pharma Inc | Substituierte oxoazaheterozyclische verbindungen |
US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
TWI290136B (en) * | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
UY26780A1 (es) * | 2000-06-15 | 2002-01-31 | Pharmacia Corp | Cicloalquil avb3 antagonistas |
PE20020382A1 (es) * | 2000-06-15 | 2002-05-10 | Pharmacia Corp | Derivados de acido heteroarilalcanoico como antagonistas de la integrina |
US6906046B2 (en) | 2000-12-22 | 2005-06-14 | Celltech R & D Inc. | Pharmaceutical uses and synthesis of benzobicyclooctanes |
CA2450589C (en) * | 2001-06-08 | 2011-12-20 | Cytokine Pharmasciences, Inc. | Isoxazoline compounds having mif antagonist activity |
US20040043988A1 (en) * | 2001-06-15 | 2004-03-04 | Khanna Ish Kurmar | Cycloalkyl alkanoic acids as intergrin receptor antagonists |
US7365205B2 (en) * | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
DE10130020A1 (de) * | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
WO2003059251A2 (en) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Antibody targeting compounds |
UA81235C2 (en) * | 2001-11-26 | 2007-12-25 | Genentech Inc | Catheter composition and uses thereof |
US20070014779A1 (en) * | 2002-11-14 | 2007-01-18 | Genentech, Inc. | Plasminogen activator variant formulations |
BR0317600A (pt) * | 2002-12-20 | 2005-11-29 | Pharmacia Corp | ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina |
AU2003297408A1 (en) * | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Thiazole compounds as integrin receptor antagonists derivatives |
MXPA05006588A (es) * | 2002-12-20 | 2005-08-16 | Pharmacia Corp | Compuestos de pirazol como derivados antagonistas del receptor de la integrina. |
RU2333203C2 (ru) * | 2002-12-25 | 2008-09-10 | Дайити Фармасьютикал Ко., Лтд. | Диаминовые производные |
US7250415B2 (en) * | 2003-06-04 | 2007-07-31 | Bristol-Myers Squibb Company | 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors |
CA2558848C (en) | 2004-03-05 | 2013-11-19 | Nissan Chemical Industries, Ltd. | Isoxazoline-substituted benzamide compound and pesticide |
EP1727542A4 (en) * | 2004-03-26 | 2009-08-05 | Cytokine Pharmasciences Inc | COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE, AND METHODS OF USE FOR INHIBITING MACROPHAGE MIGRATION INHIBITION FACTOR |
KR101324451B1 (ko) * | 2005-03-15 | 2013-10-31 | 가니얼 이뮤노테라퓨틱스 인코포레이티드 | 면역 조절제 활성을 갖는 화합물 |
DE102005044813A1 (de) | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
BRPI0617076B1 (pt) | 2005-09-02 | 2021-07-06 | Nissan Chemical Corporation | Composto benzamida substituída por isoxazolina da fórmula (1) ou sal do mesmo; composto benzamida substituido por 4-hidroxiiminametila da fórmula (2) ou sal do mesmo; pesticida; agente agroquímico; parasiticida interno ou externo para mamíferos ou aves; inseticida ou acaricida |
EP1945262A2 (en) * | 2005-10-20 | 2008-07-23 | The Scripps Research Institute | Fc labeling for immunostaining and immunotargeting |
TW200803740A (en) | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
CN103265495B (zh) | 2005-12-29 | 2016-11-16 | 莱西肯医药有限公司 | 多环氨基酸衍生物及其使用方法 |
TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
US8916148B2 (en) | 2006-11-07 | 2014-12-23 | Genentech, Inc. | Tissue plasminogen activator variant uses |
WO2008154528A2 (en) | 2007-06-13 | 2008-12-18 | E. I. Du Pont De Nemours And Company | Isoxazoline insecticides |
TWI430995B (zh) | 2007-06-26 | 2014-03-21 | Du Pont | 萘異唑啉無脊椎有害動物控制劑 |
MX2009013748A (es) | 2007-06-27 | 2010-01-26 | Du Pont | Metodo de control de plagas en animales. |
TWI600639B (zh) | 2007-08-17 | 2017-10-01 | 杜邦股份有限公司 | 製備5-鹵烷基-4,5-二氫異唑衍生物之化合物 |
KR20100075996A (ko) | 2007-10-03 | 2010-07-05 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 무척추 해충의 방제를 위한 나프탈렌 이속사졸린 화합물 |
US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
TWI583664B (zh) | 2008-04-09 | 2017-05-21 | 杜邦股份有限公司 | 羰基化合物及其製備方法 |
WO2010093706A2 (en) | 2009-02-10 | 2010-08-19 | The Scripps Research Institute | Chemically programmed vaccination |
US8765735B2 (en) * | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US9149465B2 (en) * | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US8927551B2 (en) * | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US20130172553A1 (en) * | 2009-11-25 | 2013-07-04 | Cpsi Stockholder Trust | Chiral synthesis of isoxazolines, isoxazoline compounds, and uses thereof |
UA108881C2 (xx) | 2010-05-27 | 2015-06-25 | Кристалічна форма 4-$5-$3-хлор-5-(трифторметил)феніл]-4,5-дигідро-5-(трифторметил)-3-ізоксазоліл]-n-$2-оксо-2-$(2,2,2-трифторетил)аміно]етил]-1-нафталінкарбоксаміду | |
US20150064221A1 (en) | 2012-04-17 | 2015-03-05 | Niranjan Y. Sardesai | Compounds having immunomudulator activity |
LT3538525T (lt) | 2016-11-08 | 2022-09-26 | Bristol-Myers Squibb Company | Propiono rūgštys, pakeistos 3 padėtyje, kaip alfa v integrino inhibitoriai |
US10745384B2 (en) | 2016-11-08 | 2020-08-18 | Bristol-Myers Squibb Company | Indazole derivatives as αv integrin antagonists |
MA46746A (fr) * | 2016-11-08 | 2019-09-18 | Bristol Myers Squibb Co | Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v |
US10717736B2 (en) * | 2016-11-08 | 2020-07-21 | Bristol-Myers Squibb Company | Pyrrole amides as alpha V integrin inhibitors |
CN110167934B (zh) | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
MX2020004455A (es) | 2017-11-07 | 2020-07-24 | Bristol Myers Squibb Co | Derivados de pirrolopirazina como inhibidores de integrina alfa v. |
AR114489A1 (es) * | 2018-04-12 | 2020-09-09 | Morphic Therapeutic Inc | ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA |
MX2022004406A (es) | 2019-10-16 | 2022-08-25 | Morphic Therapeutic Inc | INHIBICIÓN DE INTEGRINA A4ß7 HUMANA. |
CN111323570B (zh) * | 2020-03-25 | 2021-11-05 | 天津市宝坻区人民医院 | 基于血栓弹力图的阿司匹林药物抵抗检测方法 |
CA3228242A1 (en) * | 2021-08-13 | 2023-02-16 | Anas M. Fathallah | Compositions and methods for reducing immune intolerance and treating autoimmune disorders |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2811190A1 (de) * | 1978-03-15 | 1979-09-20 | Bayer Ag | Verfahren zur herstellung von 2-(2,2-dimethyl-3-buten-1-yl)-2-oxazolinen |
DE2852924A1 (de) * | 1978-12-07 | 1980-06-26 | Bayer Ag | Substituierte spiro-derivate von 3- (3,5-dihalogenphenyl)-oxazolidin-2,4-dionen (thion-onen), verfahren zu ihrer herstellung sowie ihre verwendung als fungizide |
US5039805A (en) * | 1988-12-08 | 1991-08-13 | Hoffmann-La Roche Inc. | Novel benzoic and phenylacetic acid derivatives |
US5084466A (en) * | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
CA2037153A1 (en) * | 1990-03-09 | 1991-09-10 | Leo Alig | Acetic acid derivatives |
NZ239846A (en) * | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
NZ239876A (en) * | 1990-09-27 | 1993-12-23 | Merck & Co Inc | Glycyl-b-alanine derivatives and pharmaceutical compositions thereof. |
IL99537A (en) * | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical preparations containing them |
DE4107857A1 (de) * | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
UA39849C2 (uk) * | 1991-03-26 | 2001-07-16 | Ф.Хоффманн-Ля Рош Аг | ПОХІДНІ N-АЦИЛ-<font face="Symbol">a</font>-АМІНОКИСЛОТИ АБО ЇХ ФІЗІОЛОГІЧНО ПРИЙНЯТНІ СОЛІ, ПРОСТІ АБО СКЛАДНІ ЕФІРИ, АМІДИ АБО ЇХ ГІДРАТИ ЯК ФАРМАЦЕВТИЧНО АКТИВНІ РЕЧОВИНИ |
US5321034A (en) * | 1991-05-07 | 1994-06-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
WO1992019595A1 (en) * | 1991-05-07 | 1992-11-12 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5220050A (en) * | 1991-05-17 | 1993-06-15 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
DE4124942A1 (de) * | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE4126277A1 (de) * | 1991-08-08 | 1993-02-11 | Cassella Ag | Hydantoinderivate |
US5239113A (en) * | 1991-10-15 | 1993-08-24 | Monsanto Company | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof |
US5227490A (en) * | 1992-02-21 | 1993-07-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
DE4207254A1 (de) * | 1992-03-07 | 1993-09-09 | Cassella Ag | 4-oxo-2-thioxoimidazolidin-derivate |
DE4212304A1 (de) * | 1992-04-13 | 1993-10-14 | Cassella Ag | Asparaginsäurederivate, ihre Herstellung und Verwendung |
DE4213634A1 (de) * | 1992-04-24 | 1993-10-28 | Cassella Ag | 2,4-Dioxo-imidazolidin-Derivate |
DE4213931A1 (de) * | 1992-04-28 | 1993-11-04 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
PT649843E (pt) * | 1992-07-15 | 2000-12-29 | Taisho Pharmaceutical Co Ltd | Derivado do tiazolino |
US5478945A (en) * | 1992-07-15 | 1995-12-26 | Taisho Pharmaceutical Co., Ltd. | Thiazoline derivatives |
DE4224414A1 (de) * | 1992-07-24 | 1994-01-27 | Cassella Ag | Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung |
SK94393A3 (en) * | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
DE69327536T2 (de) * | 1992-10-14 | 2000-07-06 | Merck & Co., Inc. | Fibrinogenrezeptor-antagonisten |
US5786373A (en) * | 1992-10-14 | 1998-07-28 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
JPH08504194A (ja) * | 1992-12-01 | 1996-05-07 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲンレセプターアンタゴニスト |
DE4302051A1 (de) * | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
DE4332168A1 (de) * | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
NZ262664A (en) * | 1993-02-22 | 1997-04-24 | Merck & Co Inc | Heterocyclic substituted derivatives, and medicaments thereof |
US5334596A (en) * | 1993-05-11 | 1994-08-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5397791A (en) * | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5430043A (en) * | 1993-08-24 | 1995-07-04 | G. D. Searle & Co. | Platelet aggregation inhibitors |
US5446056A (en) * | 1993-11-24 | 1995-08-29 | The Du Pont Merck Pharmaceutical Company | Isoxazoline compounds useful as fibrinogen receptor antagonists |
JPH09505589A (ja) * | 1993-11-24 | 1997-06-03 | ザ・デュポン・メルク・ファーマシュウティカル・カンパニー | フィブリノーゲン受容体アンタゴニストとして有用なイソオキサゾリン化合物 |
ATE198748T1 (de) * | 1993-11-24 | 2001-02-15 | Du Pont Pharm Co | Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten |
-
1995
- 1995-05-31 US US08/455,436 patent/US5849736A/en not_active Expired - Lifetime
-
1996
- 1996-05-15 IL IL11826296A patent/IL118262A/xx not_active IP Right Cessation
- 1996-05-30 AU AU60243/96A patent/AU723577B2/en not_active Ceased
- 1996-05-30 SI SI9620071A patent/SI9620071A/sl unknown
- 1996-05-30 WO PCT/US1996/007692 patent/WO1996038426A1/en not_active Application Discontinuation
- 1996-05-30 ES ES96917833T patent/ES2198483T3/es not_active Expired - Lifetime
- 1996-05-30 PL PL96323835A patent/PL323835A1/xx unknown
- 1996-05-30 HU HU9900102A patent/HUP9900102A3/hu unknown
- 1996-05-30 JP JP8536579A patent/JPH11504651A/ja active Pending
- 1996-05-30 CA CA002222147A patent/CA2222147A1/en not_active Abandoned
- 1996-05-30 SK SK1620-97A patent/SK162097A3/sk unknown
- 1996-05-30 CZ CZ973743A patent/CZ374397A3/cs unknown
- 1996-05-30 RO RO97-02195A patent/RO117324B1/ro unknown
- 1996-05-30 DE DE69629116T patent/DE69629116T2/de not_active Expired - Fee Related
- 1996-05-30 CN CN96195931A patent/CN1202893A/zh active Pending
- 1996-05-30 KR KR1019970708677A patent/KR19990022198A/ko not_active Application Discontinuation
- 1996-05-30 EP EP96917833A patent/EP0832076B1/en not_active Expired - Lifetime
- 1996-05-30 BR BR9609151A patent/BR9609151A/pt unknown
- 1996-05-30 NZ NZ309944A patent/NZ309944A/en unknown
- 1996-05-30 EA EA199700452A patent/EA000924B1/ru not_active IP Right Cessation
- 1996-05-30 AT AT96917833T patent/ATE245150T1/de not_active IP Right Cessation
- 1996-05-30 EE EE9700312A patent/EE9700312A/xx unknown
- 1996-05-31 ZA ZA9604486A patent/ZA964486B/xx unknown
- 1996-06-14 TW TW085107183A patent/TW454007B/zh not_active IP Right Cessation
-
1997
- 1997-11-24 LT LT97-182A patent/LT4416B/lt not_active IP Right Cessation
- 1997-11-25 US US08/978,295 patent/US6114328A/en not_active Expired - Lifetime
- 1997-12-29 LV LVP-97-239A patent/LV12046B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1996038426A1 (en) | 1996-12-05 |
CN1202893A (zh) | 1998-12-23 |
EA000924B1 (ru) | 2000-06-26 |
LT4416B (lt) | 1998-12-28 |
ES2198483T3 (es) | 2004-02-01 |
NZ309944A (en) | 1999-10-28 |
EA199700452A1 (ru) | 1998-10-29 |
TW454007B (en) | 2001-09-11 |
CA2222147A1 (en) | 1996-12-05 |
SK162097A3 (en) | 1999-04-13 |
DE69629116D1 (de) | 2003-08-21 |
EP0832076B1 (en) | 2003-07-16 |
US6114328A (en) | 2000-09-05 |
DE69629116T2 (de) | 2004-04-08 |
AU6024396A (en) | 1996-12-18 |
HUP9900102A2 (hu) | 1999-05-28 |
LV12046B (en) | 1998-09-20 |
IL118262A0 (en) | 1996-09-12 |
PL323835A1 (en) | 1998-04-27 |
JPH11504651A (ja) | 1999-04-27 |
BR9609151A (pt) | 1999-06-29 |
SI9620071A (sl) | 1998-12-31 |
EP0832076A1 (en) | 1998-04-01 |
LT97182A (en) | 1998-07-27 |
US5849736A (en) | 1998-12-15 |
ATE245150T1 (de) | 2003-08-15 |
RO117324B1 (ro) | 2002-01-30 |
AU723577B2 (en) | 2000-08-31 |
LV12046A (lv) | 1998-05-20 |
IL118262A (en) | 2003-02-12 |
CZ374397A3 (cs) | 1998-12-16 |
KR19990022198A (ko) | 1999-03-25 |
EE9700312A (et) | 1998-06-15 |
HUP9900102A3 (en) | 2001-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA964486B (en) | Isoxazoline and isoxazole fibrinogen receptor antagonists. | |
HU9601414D0 (en) | Novel isoxazoline and isoxazole fibrinogen receptor antagonists | |
DK0730589T3 (da) | Isoxazolinforbindelser, der er nyttige som fibrinogenreceptorantagonister | |
TW363064B (en) | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | |
ES2124905T3 (es) | Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad. | |
GR3029931T3 (en) | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa. | |
DK58291D0 (da) | Krystalinsk stof og dets fremstilling | |
WO2000029406A3 (en) | Novel isoxazoline fibrinogen receptor antagonists | |
WO2005035495A3 (en) | Fibrinogen receptor antagonists and their use | |
MX9709081A (es) | Nuevos antagonistas del receptor fibrinogeno de isoxazolina e isoxazol. | |
DE3278472D1 (en) | 6-fluoro-3-(3-(1-heterocyclo)propyl)-1,2-benzisoxazoles, a process for their preparation, pharmaceutical compositions thereof and their use as medicaments | |
BR9815399A (pt) | Processo para formação de um composto, processo para preparação do composto e composto |